Asbestos exposure, pleural mesothelioma, and serum osteopontin levels

New England Journal of Medicine

Volumn 353, Issue 15, 2005, Pages 1564-1573

  Pass, Harvey I ^a,f   Lott, Dan ^c   Lonardo, Fulvio ^a   Harbut, Michael ^a   Liu, Zhandong ^b   Tang, Naimei ^a   Carbone, Michele ^d   Webb, Craig ^e   Wali, Anil ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wayne State University   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; OSTEOPONTIN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; ROC CURVE; THORAX RADIOGRAPHY; TUMOR CELL;

AGED; ASBESTOS; ASBESTOSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; OCCUPATIONAL EXPOSURE; OSTEOPONTIN; PLEURAL NEOPLASMS; REGRESSION ANALYSIS; ROC CURVE; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 26444506232     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa051185     Document Type: Article

References (47)

1. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5:290-8.
2. Cullen MR, Barnett MJ, Balmes JR, et al. Predictors of lung cancer among asbestos-exposed men in the {beta}-carotene and Retinol Efficacy Trial. Am J Epidemiol 2005;161:260-70.
3. Ebert W, Hoppe M, Muley T, Drings P. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Anticancer Res 1997;17:2875-8.
4. Pettersson T, Froseth B, Riska H, Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988;94:1037-9.
5. Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104-7.
6. Roboz J, Chahinian AP, Holland JF, Silides D, Szrajer L. Early diagnosis and monitoring of transplanted human malignant mesothelioma by serum hyaluronic acid. J Natl Cancer Inst 1989;81:924-8.
7. Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WT. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984;54:2195-9.
8. Boersma A, Degand P, Biserte G. Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Eur Physiopathol Respir 1980;16:41-5.
9. Hellstrom PE, Friman C, Teppo L. Malignant mesothelioma of 17 years' duration with high pleural fluid concentration of hyaluronate. Scand J Respir Dis 1977;58:97-102.
10. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001;92:1224-30.
11. Pluygers E, Baldewyns P, Minette P, Beauduin M, Gourdin P, Robinet P. Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations. Eur J Cancer Prev 1992;1:129-38.
12. Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust N Z J Med 1999;29:765-9.
13. Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001;119:1138-42.
14. Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 1999;25:25-32.
15. Marukawa M, Hiyama J, Shiota Y, et al. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma. Acta Med Okayama 1998;52:119-23.
16. Bonfrer JM, Schouwink JH, Korse CM, Baas P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 1997;17:2971-3.
17. Almudevar BE, Garcia-Rostan Perez GM, Garcia Bragado F, Jimenez C. Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women: a case report with differential diagnosis and review of the literature. Histopathology 1997;31:267-73.
18. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
19. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004;10:849-59.
20. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
21. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-11.
22. Ding L, Zheng S. Expression and clinical significance of osteopontin in colorectal cancer and liver metastatic tissues. Zhonghua Wai Ke Za Zhi 2002;40:773-5. (In Chinese.)
23. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-32.
24. Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004;10:3474-8.
25. Brakora KA, Lee H, Yusuf R, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004;93:361-5.
26. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
27. Denhardt D. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124:xvi-xviii.
28. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res 2004;121:228-41.
29. Sandhu H, Dehnen W, Roller M, Abel J, Unfried K. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 2000;21:1023-9.
30. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978;118:1-120.
31. Selikoff IJ, Churg J, Hammond EC. Asbestos exposure and neoplasia. CA Cancer J Clin 1984;34:48-56.
32. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14:1-12.
33. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
34. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77. [Erratum, Clin Chem 1993;39:1589.]
35. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
36. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-7.
37. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-804.
38. Idem. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-25.
39. Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 2002;26:55-65.
40. Schottenfeld D, Fraumeni JF Jr. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, 1982.
41. Safety and health topics: asbestos. Washington, D.C.: National Institute for Occupational Safety and Health, 2003.
42. Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med 2004;61:438-41.
43. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184-90.
44. Schneider S, Yochim J, Brabender J, et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004;10:1588-96.
45. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004;13:487-91.
46. Martinetti A, Bajetta E, Ferrari L, et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 2004;11:771-9.
47. McIntosh MW, Drescher C, Karlan B, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004;95:9-15.